Truist Reiterates Buy Rating for Boston Scientific (BSX)
Key takeaways
- Truist Reiterates Buy Rating for Boston Scientific (BSX) Muhammad Ali Khalid Sat, June 13, 2026 at 10:29 PM GMT+7 2 min read BSX TFC Boston Scientific Corp.
- On June 4, Truist significantly decreased the price target on Boston Scientific Corp.
- Truist believes that Boston Scientific’s current valuation is still quite distant from its strong underlying financials in spite of these particular product challenges.
Truist Reiterates Buy Rating for Boston Scientific (BSX) Muhammad Ali Khalid Sat, June 13, 2026 at 10:29 PM GMT+7 2 min read BSX TFC Boston Scientific Corp. (NYSE:BSX) is one of the 12 best buy-the-dip stocks to invest in now.
On June 4, Truist significantly decreased the price target on Boston Scientific Corp. (NYSE:BSX), from $85 to $64, while maintaining a Buy rating on the stock. The firm cited recent management remarks indicating that the Watchman device’s growth in the U.S. market was slowing.
Truist believes that Boston Scientific’s current valuation is still quite distant from its strong underlying financials in spite of these particular product challenges. According to Truist, the company is still projecting a strong financial profile, with a double-digit increase in EPS and at least 7% growth in top-line revenue.